Loading...
XHKG
2170
Market cap49mUSD
Jul 09, Last price  
1.41HKD
1D
-0.70%
1Q
-30.54%
Name

Suzhou Basecare Medical Co Ltd

Chart & Performance

D1W1MN
XHKG:2170 chart
P/E
P/S
1.43
EPS
Div Yield, %
Shrs. gr., 5y
0.51%
Rev. gr., 5y
23.53%
Revenues
233m
-22.01%
32,609,00055,685,00081,109,000107,299,000140,901,000207,976,000299,109,000233,270,000
Net income
-223m
L-5.73%
-154,877,000-531,336,000-877,052,000-143,651,000-123,163,000-191,685,000-237,029,000-223,455,000
CFO
-160m
L-30.16%
-26,695,000-38,145,000-64,288,000-197,852,000-188,769,000-267,234,000-229,116,000-160,010,716

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and manufacturing of genetic testing solutions specifically for assisted reproduction, alongside the distribution of related medical devices and instruments. Its extensive product line includes a range of genetic test kits for reproductive health. These comprise pre-implantation genetic tests such as PGT-A, designed to screen for chromosomal aneuploidies; PGT-M, which identifies single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits, used to detect chromosomal structural rearrangements often linked to recurrent miscarriages. Additionally, Basecare offers prenatal test kits (CNV kits) and postnatal test kits (WES kits). Complementing its genetic testing offerings, the company supplies various specialized medical equipment, including liquid nitrogen storage dewars, cryostorage systems, automated workstations, sperm quality analyzers, and next-generation sequencing (NGS) sequencers. Beyond manufacturing and sales, Basecare also provides marketing services and develops software for its medical devices and instruments. Its primary clientele consists of hospitals and reproductive clinics.
IPO date
Employees
479
Domiciled in
CN
Incorporated in

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT